Aurinia Pharmaceuticals (AUPH) shares rose by 6.5% to $17.53 in the last trading session, driven by significant trading volume and a cumulative gain of 8.2% over the past month. The increase reflects positive investor sentiment surrounding the company’s growth prospects beyond its first FDA-approved treatment for active lupus nephritis, Lupkynis. Key focus areas include the pipeline product aritinercept, a dual BAFF/APRIL inhibitor, and the recent acquisition of Kezar Life Sciences, which introduced zetomipzomib, a promising late-stage therapy.
The company is expected to announce quarterly earnings of $0.21 per share, marking a 31.3% year-over-year increase, with revenues projected at $83.3 million, a 19% rise from the previous year. Despite no changes in EPS estimates over the last 30 days, Aurinia’s stock currently holds a Zacks Rank of #2 (Buy), suggesting strong market confidence in the firm’s path forward.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
